Wells Fargo’s Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share IBER.WS Stock Holding History

Wells Fargo’s Portfolio IBER.WS Stock Details IBER.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-122,354	Closed	-$2.18K	–	7867
2022 Q4	$2.18K	Hold	122,354	–	–	﹤0.01%	5995
2022 Q3	$10K	Hold	122,354	–	–	﹤0.01%	5703
2022 Q2	$10K	Hold	122,354	–	–	﹤0.01%	5772
2022 Q1	$24K	Hold	122,354	–	–	﹤0.01%	5954
2021 Q4	$66K	Hold	122,354	–	–	﹤0.01%	5843
2021 Q3	$73K	Buy	122,354 +38,612	+46%	+$25.9K	﹤0.01%	5501
2021 Q2	$64K	Buy	+83,742	New	+$50.9K	﹤0.01%	5465

Other funds holding IBER.WS

LCM

Lynwood Capital Management Toronto, Ontario, Canada $16.9M AUM 19.31% 1-Year Est. Return

Wells Fargo's IBER.WS Position: Q1 2023 in Review

Wells Fargo sold out of Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share (IBER.WS) in Q1 2023, closing a stake of 122,354 shares — an estimated $2.18K sold.

Wells Fargo first reported a position in IBER.WS in Q2 2021 and held it in 7 quarters. The position peaked at $73K in Q3 2021. 1 fund tracked by Wall St. Rank holds IBER.WS as of Q1 2023.

Wells Fargo reported no remaining Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share position as of Q1 2023 after selling out during the quarter.
Wells Fargo sold 122,354 Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share shares in Q1 2023, an estimated $2.18K.
Wells Fargo first reported a position in Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share in Q2 2021 and held it in 7 quarters.
Wells Fargo's Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share position peaked at $73K in Q3 2021.
1 fund tracked by Wall St. Rank held Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share as of Q1 2023.

Based on Wells Fargo's 13F filing for Q1 2023, filed 12 May 2023.